Rockefeller Capital Management L.P. Acquires 43,983 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Rockefeller Capital Management L.P. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 288,834 shares of the medical research company's stock after acquiring an additional 43,983 shares during the quarter. Rockefeller Capital Management L.P. owned about 0.08% of Thermo Fisher Scientific worth $150,304,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Howard Capital Management Group LLC lifted its stake in Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after buying an additional 286 shares in the last quarter. Principal Financial Group Inc. grew its position in Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after purchasing an additional 225,568 shares in the last quarter. M&T Bank Corp raised its stake in Thermo Fisher Scientific by 4.2% during the 3rd quarter. M&T Bank Corp now owns 113,347 shares of the medical research company's stock valued at $70,113,000 after purchasing an additional 4,584 shares during the period. Virtu Financial LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter worth $638,000. Finally, Anchor Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 1.7% during the third quarter. Anchor Investment Management LLC now owns 11,366 shares of the medical research company's stock valued at $7,031,000 after buying an additional 195 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Remove Ads

Thermo Fisher Scientific Stock Performance

TMO traded up $10.45 during trading on Monday, hitting $448.60. The stock had a trading volume of 2,370,499 shares, compared to its average volume of 1,701,500. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a 50 day simple moving average of $507.90 and a 200-day simple moving average of $537.62. The firm has a market cap of $169.24 billion, a PE ratio of 27.14, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.38%. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last ninety days. Insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Citigroup cut their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Barclays lowered their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.